Department of Neurology, Northwestern University, Chicago, IL, USA.
Department of Clinical Oncology Pharmacy, University of Kentucky, Lexington, KY, 40536-0093, USA.
J Neurooncol. 2017 Dec;135(3):593-599. doi: 10.1007/s11060-017-2612-8. Epub 2017 Aug 28.
The novel anti-mitotic based tumor treating fields (TTFields) is FDA approved for recurrent glioblastoma. Recently the phase III upfront trial combining the Novo TTF-100A device, called Optune, with temozolomide following concurrent radiation therapy and chemotherapy, demonstrated improvement in survival. Wider use of this novel therapy is expected. The most common adverse event is dermatologic, which dominates compared to the next most frequently observed adverse event of headaches, the incidence of which was even in both arms in the phase III registration trial for recurrent glioblastoma. Our case review outlines the presentation, treatment, and outcome of representative patients using TTFields. In summary, preventative strategies to inform and educate patients and operators can prevent many of these dermatological events. Skin toxicity in the setting of concurrent use of TTFields with other therapies such as bevacizumab is an unknown and will need to be closely followed.
新型抗有丝分裂的肿瘤治疗电场（TTFields）已获得 FDA 批准用于复发性脑胶质瘤。最近，III 期临床试验将 Novo TTF-100A 设备（称为 Optune）与替莫唑胺联合应用，在同步放化疗后使用，结果显示生存时间有所改善。预计这种新型疗法的应用将更加广泛。最常见的不良反应是皮肤病相关的，与下一个最常观察到的头痛不良反应相比，这种不良反应更为常见，在复发性脑胶质瘤的 III 期注册试验中，这两种不良反应在两个治疗组中都很常见。我们的病例回顾总结了使用 TTFields 的代表性患者的表现、治疗和结果。总之，通过信息告知和教育患者和操作人员，可以预防许多皮肤病事件。在 TTFields 与其他疗法（如贝伐单抗）联合应用的情况下，皮肤毒性是未知的，需要密切关注。
